Apriori Bio offers a platform for creating variant-resilient vaccines and provides real-time insights to prepare for future outbreaks.
Apriori Bio has raised $1.1M in total funding. The most recent round was Grant. The last funding was announced in July 2024.
Apriori Bio's investors include Flagship Pioneering, Coalition for Epidemic Preparedness Innovations.
Apriori Bio is headquartered in Boston, United States.
Apriori Bio offers a platform for creating variant-resilient vaccines and provides real-time insights to prepare for future outbreaks.
Apriori Bio is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Apriori Bio — Funding & Investors." VCBacked, July 8, 2024, https://www.vcbacked.co/company/apriori-bio. Accessed November 15, 2026.
VCBacked. (2024). Apriori Bio — Funding & Investors. Retrieved November 15, 2026, from https://www.vcbacked.co/company/apriori-bio
{{cite web |title=Apriori Bio — Funding & Investors |url=https://www.vcbacked.co/company/apriori-bio |website=VCBacked |access-date=November 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Apriori Bio? Request a listing update